Navigation Links
U.S. FDA Approves Requip(R) XL(TM), the First and Only Oral Once-Daily Non-Ergot Dopamine Agonist for Parkinson's Disease
Date:6/13/2008

Requip XL Improved Symptoms in Patients Not Optimally Controlled with Levodopa and Reduced Patients' "Off" Time by Nearly Two Hours Per Day

RESEARCH TRIANGLE PARK, N.C., June 13 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE: GSK) today announced the approval of Requip(R) XL(TM) (ropinirole extended-release tablets) in the U.S. for the treatment of the signs and symptoms of idiopathic Parkinson's disease. Requip XL is the first and only oral once-daily non-ergot dopamine agonist indicated for Parkinson's disease. The product should be available in pharmacies in mid-July 2008.

Patients with Parkinson's disease may experience what is commonly known as "off" time when their medication wears off and their symptoms return. Symptoms such as slowness of movement, tremor, and rigidity can be problematic for these patients, causing simple activities and movement to become difficult. Results from a pivotal efficacy and safety trial showed that adding Requip XL to patients' existing levodopa (l-dopa) therapy reduced the amount of "off" time experienced by patients with Parkinson's disease by 2.1 hours per day on average, compared to baseline. Specifically, comparing the experience of the group treated with Requip XL versus the placebo group, the adjusted mean difference in the reduction of "off" time was -1.7 hours, which was statistically significant.

"Many patients require multiple doses of one or more medications to control their Parkinson's symptoms, which makes taking their medicines correctly and at the right times challenging. In addition, patients with Parkinson's disease may have trouble completing routine activities of daily living and self-care," said clinical investigator Rajesh Pahwa, M.D., professor of Neurology
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
2. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
3. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
4. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
5. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
6. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
7. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
8. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
9. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
10. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
11. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)...  Heska Corporation (Nasdaq: HSKA ) announces ... Its Third Quarter 2014 Earnings Conference Call on the ... 11:00 a.m. (EDT)Where: , www.heska.com (click on ... page of this website)How:Live over the Internet -- Simply ... Alternatively, you may use the following teleconference access numbers:  ...
(Date:10/25/2014)... Md. , Oct. 24, 2014  The ... highlighted the latest results achieved by ... system. The National Precursor Log ... at the point of sale and helps flag ... narcotics agents often set up NPLEx "watch lists" ...
(Date:10/25/2014)... Metanome, Inc. , a Houston -based ... the genomic sequencing provider for Seres Health,s ( ... SER 109, an Ecobiotic® therapeutic for the treatment of ... Metanome has provided genomic sequencing services in ... genomic characterization has enabled the study of the microbiota ...
Breaking Medicine Technology:Webcast Alert: Heska Announces Third Quarter 2014 Earnings Conference Call Webcast 2Kentucky's NPLEx Technology Making Significant Progress 2Metanome Selected as Metagenomics Provider for Seres Health Clinical Trial 2
... FORD, Pa., Oct. 12, 2011 Endo Pharmaceuticals (Nasdaq: ... results on October 27, 2011 and will host a conference ... discuss these results.   David P. Holveck, president ... Ivan Gergel, executive vice president of R&D, Alan Levin, executive ...
... Aircraft Medical ("Aircraft"), the UK medical devices company, today ... Covidien (NYSE: COV ), a leading global ... billion, and 41,000 employees worldwide. Under the ... Aircraft,s proprietary McGRATH ® MAC video laryngoscope in ...
Cached Medicine Technology:Endo Pharmaceuticals to Announce Third Quarter 2011 Financial Results on October 27, 2011 2Aircraft Medical Signs Multinational Distribution Agreement with Covidien for McGRATH® MAC Video Laryngoscope 2
(Date:10/25/2014)... A large influx of international aid is needed, and ... thousands of deaths from the widening Ebola crisis, a ... a specially designed mathematical model, the researchers looked at ... densely populated county of hard-hit Liberia -- Montserrado County, ... researchers said that if international aid isn,t delivered to ...
(Date:10/25/2014)... (HealthDay News) -- October,s shorter, darker days can trigger ... according to an expert. People affected by ... tired, lack motivation and even have trouble getting out ... suicide, said Dr. Angelos Halaris, a professor in the ... Chicago Stitch School of Medicine. "Seasonal affective disorder ...
(Date:10/22/2014)... On October 22, CBS will air ... diseases both fictional and real. The Charles E ... committed to advocacy and philanthropy in the battle against ... opportunity to impart truth and clarity about this misunderstood ... many misconceptions about Morgellons Disease (MD) and ...
(Date:10/22/2014)... 22, 2014 For Dr. Iris Hunter, a ... it’s an extension of her life’s mission. Her extensive experience ... the owner of FirstLight HomeCare, make it clear that Hunter’s ... me that my work makes a difference in the lives ... spirit, so after much research, I felt ready to start ...
(Date:10/22/2014)... Kentucky (PRWEB) October 22, 2014 Shriners ... agreement that will change the current location of Shriners ... to South Limestone across from the University of Kentucky ... a state-of-the-art ambulatory care center, owned and operated by ... the orthopaedic needs of children and their families well ...
Breaking Medicine News(10 mins):Health News:Experts Predict 'Catastrophic' Ebola Epidemic in West Africa if Aid Delayed 2Health News:Dark Days Here for Folks With Seasonal Depression 2Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 2Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 3Health News:Dr. Iris Hunter to Host Grand Opening of FirstLight HomeCare Tomorrow 2Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 2Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 3
... than half of Americans know two particular fats boost ... Fewer than half of Americans realize there are two ... a new survey shows. , So, while many have ... fats and saturated fats, the American Heart Association (AHA) ...
... specific pieces of non-coding genetic material known as microRNAs ... cancer to other parts of the body. Researchers at ... Ohio State University Medical Center in Columbus have identified ... The findings, reported at the annual meeting of the ...
... ... Center, ... planning and interiors,firm, has transformed a shuttered South of Market warehouse ... As the new "front door" for the downtown university, the,former Swallow ...
... Indiana experienced a 50 percent membership ... growth since 2007, ... this 14-year-old, not-for-profit,Indiana managed health care plan -- surpassing the 300,000 mark ... 2007, the,company has also grown its employee base by 182 percent -- ...
... CHAPEL HILL, N.C., May 30 Creating an ... of a new product,s introduction.,A product,s promotion relies ... it.,Top benchmark companies ensure that they create effective, ... of a new product., The detailed report ...
... 30 Members of District,1199C of the National ... morning (Friday) ratified a four-year contract agreement with,Hahnemann ... increase in,wages and benefits., District 1199C represents ... reached with the hospital following some 16 and ...
Cached Medicine News:Health News:Some Fats Deserve Change of Heart 2Health News:Jefferson, Ohio State team find gene signature profile for metastasis 2Health News:Golden Gate University Opens New Student Services Center 2Health News:MDwise Enrollment Exceeds 300,000 Members 2Health News:Managing Cross-Functional Teams for Pharmaceutical Product Commercialization Excellence 2
Used for drainage and retrograde pyelogram. Supplied sterile in peel-open packages. Intended for one-time use....
Used for retrograde pyelogram. Supplied sterile in peel-open packages. Intended for one-time use....
Used for directing a flexible tipped wire guide in the ureter. The angled tip allows passage of the catheter past a ureteral stone in preparation for E.S.W.L. Supplied sterile in peel-open packages. ...
These flexible stone retrieval devices are reusable, 3 Fr in diameter, with a working length of either 60 cm or 115 cm...
Medicine Products: